We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Targeting Diseased Areas using Enzyme-Sensitive Contrast Agents for MRI

By MedImaging staff writers
Posted on 16 Jun 2008
Magnetic resonance imaging (MRI) has become a standard modality in clinical diagnosis due to the use of contrast agents, which enable the contrast between healthy tissue and diseased tissue to be increased. However, the agents currently used clinically do not allow the identification of particular pathologies or of the affected area of the body. The recent work of two French teams has brought hope in this area.

The recent research of two CNRS (Centre National de la Recherche Scientifique; Vandoeuvre-lès-Nancy [near Nancy], France) teams from Orleans and Gif-sur-Yvette (Orleans' Centre de Biophysique Moléculaire and the Institut de Chimie des Substances Naturelles in Gif-sur-Yvette [near Paris]) have demonstrated that by using a new class of contrast agents sensitive to enzymes, it is possible to locate the affected part of the body. The molecules act as switches--when they encounter a specific enzyme, this initiates a cascade reaction, leading to the activation of the contrast agent, which then becomes detectable in an MRI image. The systems have two positions--they are "off” in the absence of the enzyme, and "on” if present. Therefore, an image is only received when the contrast agents are activated.

The reactions caused by certain enzymes may be an indication of the state of the cells, and be interpreted as the signature of a given disease process. In the future, detection of enzymes due to these contrast agents should enable clinicians to diagnose a disease with a simple MRI examination. Moreover, the system can be modulated and is potentially applicable to a large variety of enzymes, and, therefore, pathologies.

Understanding the mechanism of these new molecules for medical imaging constitutes a major advance in visualizing molecular processes in vivo, as well as in detecting pathologies.

Founded in 1939 by French governmental decree, CNRS' goals include: to evaluate and carry out all research capable of advancing knowledge and bringing social, cultural, and economic benefits for society; contribute to the application and promotion of research results; develop scientific information and support research training; and participate in the analysis of the national and international scientific climate and its potential for evolution to develop a national policy.


Related Links:
CNRS
Pocket Fetal Doppler
CONTEC10C/CL
New
Ultrasound Needle Guidance System
SonoSite L25
Computed Tomography System
Aquilion ONE / INSIGHT Edition
X-ray Diagnostic System
FDX Visionary-A

Channels

Nuclear Medicine

view channel
Image: The diagnostic tool could improve diagnosis and treatment decisions for patients with chronic lung infections (Photo courtesy of SNMMI)

Novel Bacteria-Specific PET Imaging Approach Detects Hard-To-Diagnose Lung Infections

Mycobacteroides abscessus is a rapidly growing mycobacteria that primarily affects immunocompromised patients and those with underlying lung diseases, such as cystic fibrosis or chronic obstructive pulmonary... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.